Revisions to the ICC and WHO classifications of AML and MDS

Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses recent revisions to the International Consensus Classification (ICC) and World Health Organization (WHO) classifications of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), highlighting differences between the two systems. Dr Loghavi comments on the use of various genetic alterations to define AML and MDS, and addresses the novel MDS/AML entity recognized by the ICC. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.